Skip to main content
. 2017 Aug 28;12(8):e0183055. doi: 10.1371/journal.pone.0183055

Table 1. Clinical characteristics of the participants.

Variables Total QTc interval t/x2 p
≤440 ms >440 ms
n 2904 2406 498
Age (year) 56.1±13.5 55.3±13.5 55.4±12.7 –6.638 0.000
Female, n (%) 1380(47.5) 1030(42.8) 350(70.3) 124.9 0.000
BMI (kg/m2) 24.9±3.7 25.0±3.7 24.6±3.9 2.249 0.025
SBP (mmHg) 135±17 134±17 137±18 –3.393 0.001
DBP (mmHg) 80±10 80±10 80±11 –0.142 0.887
Diabetic duration (year) 4.0(1.5–9.0) 4.0(1.5–8.0) 4.0(1.5–8.0) 0.335
Hypoglycaemic treatments
 Lifestyle intervention alone, n(%) 312(10.7) 266(11.1) 46(9.2) 1.423 0.233
 Insulin, n(%) 861(29.6) 668(27.8) 193(38.8) 23.90 0.000
 Insulin-secretagogues, n(%) 1160(39.9) 980(40.7) 180(36.1) 3.619 0.057
 Insulin-sensitizers, n(%) 1860(64.0) 1548(64.3) 312(62.7) 0.511 0.475
Hypertension, n(%) 1077(37.1) 840(34.9) 237(47.6) 28.42 0.000
Statins medication, n(%) 1071(36.9) 872(36.2) 199(40.0) 2.499 0.118
Smoking, n(%) 883(30.4) 720(29.9) 163(32.7) 1.535 0.215
TG (mmol/L) 1.61(1.02–2.58) 1.60(1.01–2.57) 1.63(1.07–2.61) 0.465
TC (mmol/L) 4.72±1.25 4.69±1.30 4.78±1.29 –0.617 0.517
HDLC (mmol/L) 1.07±0.28 1.07±0.28 1.08±0.29 –0.842 0.400
LDLC (mmol/L) 2.51±0.82 2.49±0.81 2.54±0.89 –0.933 0.351
UA (μmol/L) 285±101 286±98 282±113 0.618 0.536
HOMA-IR 2.58(1.55–4.14) 2.52(1.52–4.03) 2.91(1.69–4.51) 0.000
HbA1c (%) 8.23±1.25 8.15±1.23 8.60±1.28 –7.247 0.000
M-FPG (mmol/L) 7.47±0.97 7.43±0.95 7.68±1.03 –5.286 0.000
SD-FPG (mmol/L) 1.35±0.44 1.34±0.43 1.36±0.44 –0.437 0.662
M-PPG (mmol/L) 13.47±1.79 13.41±1.78 13.89±1.84 –5.431 0.000
SD-PPG (mmol/L) 2.11±0.68 2.05±0.65 2.40±0.76 –10.556 0.000
QTc interval (ms) 420±31 402±24 458±20 –48.633 0.000

QTc interval: heart rate-corrected QT interval; FPG: fasting plasma glucose; PPG: 2-hour postprandial plasma glucose; SD-FPG: standard deviation of FPG; SD-PPG: standard deviation of PPG; M-FPG: mean of FPG; M-PPG: mean of PPG.